Streptococcus zooepidemicus (Sz) and Streptococcus equi (Se) share 98% DNA sequence homology, but display different pathogenic properties. Infection by one organism does not cross-protect against the other. To better understand pathogenic differences between these organisms and gain information about which proteins are expressed in horses infected experimentally with Se, intrauterine Sz or naturally with respiratory Sz we compared antibody specificities of convalescent sera using ELISA. These comparisons were based on sets of 8 and 14 immunoreactive recombinant proteins of Se strain CF32 and Sz strain NC78, respectively. Sera from donkeys that were previously naturally affected with strangles and later developed Sz pneumonia secondary to an experimental influenza challenge were also included. Serum antibody responses were quantitatively and qualitatively much greater following recovery from strangles than following respiratory Sz infection. Increased reactions to Se proteins IdeE2, Se75.3, Se46.8, Se18.9 and Se42.0 were observed for the majority of strangles sera but not for sera from respiratory Sz infection cases. Reactions of sera from Sz respiratory disease to Sz proteins varied greatly and were mostly to HylC and ScpC. Interestingly, sera of donkey recovered from Sz bronchopneumonia did not show increased antibody reaction to any of the proteins even though these donkeys had also recovered from clinical strangles 6 months previously. Only 1/5 mare with Sz placentitis presented increased serum antibody responses to MAP. In conclusion, adaptive immune responses to Se of horses with strangles are stronger and involve a greater number of proteins than adaptive immune responses to Sz infection of the lower respiratory tract. In an effort to develop an improved vaccine against Se, modified live strain of EHV-1, RacH was constructed to express three recombinant antigens of Se SeM, IdeE and Se18.9. Two groups of 10 and 2 ponies were vaccinated intramuscularly or intranasally, respectively. Another group (n=6) vaccinated with empty RacH served as controls. Sera from 2/3 ponies from each vaccination groups and 1/2 serum from IN vaccinated ponies showed increased serum neutralizing antibodies to EHV-1. ELISA detected no significant increase in antibodies to proteins. Only one IM and IN vaccinated pony showed serum bactericidal activity post vaccination.

Streptococcus suis et Streptococcus du groupe B (GBS) sont deux bactéries encapsulées qui induisent des pathologies similaires chez l’homme et/ou l’animal, incluant septicémies et méningites. La capsule polysaccharidique (CPS) est un facteur de virulence clé de ces deux pathogènes et les anticorps (Ac) anti-CPS présentent un bon potentiel protecteur. Néanmoins, ces molécules sont faiblement immunogéniques et les mécanismes de la génération de la réponse humorale anti-CPS demeurent méconnus. L’objectif principal de cette thèse était d’évaluer les caractéristiques et les mécanismes du développement de la réponse Ac dirigée spécifiquement contre les CPS de S. suis et GBS, ainsi que l’effet de la biochimie de la CPS dans cette réponse. Nous avons étudié S. suis types 2 et 14 et GBS types III et V, dont les CPS présentent plusieurs similarités dans leurs compositions et leurs structures, incluant la présence d’acide sialique, un sucre potentiellement immunosuppresseur, tout en possédant une antigénicité propre. Nous avons tout d’abord analysé la nature de la réponse Ac anti-CPS sérique face à la bactérie entière. Les souris infectées par S. suis développent une réponse très faible (S. suis type 2) voire insignifiante (S. suis type 14) de profil isotypique restreint à l’IgM et sont incapables de monter une réponse mémoire efficace face à une seconde infection. Un profil similaire est obtenu chez le porc infecté par S. suis type 2. On détecte des titres d’IgM anti-CPS significatifs chez les souris infectées par GBS (type III ou V). Toutefois, la magnitude de la réponse reste globalement faible et aucune commutation de classe n’est observée. Nous avons ensuite examiné l’influence de la biochimie de la CPS sur ces profils de réponse en conduisant des expériences avec la CPS hautement purifiée de ces pathogènes. Tandis que la CPS de GBS type III administrée aux souris conserve des propriétés immunogéniques similaires à celles observées durant l’infection par la bactérie intacte, les CPS de S. suis type 2 et GBS type V perdent toute capacité à induire une réponse Ac spécifique. L’analyse de l’interaction in vitro des CPS avec les cellules dendritiques (DC) murines, des acteurs clés dans la détection des pathogènes et l’orchestration des réponses immunitaires subséquentes, révèle que ces molécules stimulent la production de niveaux conséquents de chémokines via différents récepteurs. Néanmoins, les CPS sont inaptes à induire la sécrétion de cytokines et elles interfèrent avec la capacité des DC à exprimer BAFF, une cytokine clé dans la différenciation des lymphocytes B en plasmocytes. L’utilisation de CPS chimiquement désialylées démontre que l’acide sialique ne joue aucun rôle immunosuppresseur majeur dans le développement de la réponse Ac dirigée contre les CPS purifiées de S. suis ou GBS, ni sur l’interaction des CPS avec les DC in vitro, ni sur profil de la réponse in vivo. D’autres propriétés biochimiques intrinsèques à ces CPS seraient responsables de l’inaptitude de l’hôte infecté à monter une réponse Ac adéquate et les identifier constituera un outil précieux pour une meilleure compréhension de l’immunopathogénèse de S. suis et GBS ainsi que pour développer des moyens de lutte efficaces contre ces bactéries. / Streptococcus suis and Group B Streptococcus (GBS) are two encapsulated bacteria that induce similar pathologies in humans and/or animals, including septicemia and meningitis. The capsular polysaccharide (CPS) is a major virulence factor for both pathogens and CPS-specific antibodies (Ab) display a good protective potential. However, CPSs are weak immunogenic molecules and the mechanisms of the generation of the CPS-specific humoral response remain poorly known. Thus, the main objective of this thesis was to evaluate the characteristics and the mechanisms of the development of the Ab response directed against S. suis and GBS CPSs, as well as the influence of the biochemistry of the CPS on this response. We worked with S. suis types 2 and 14 and GBS types III and V, whose CPSs present several similarities in their compositions and structures, including the presence of sialic acid, a potentially immunosuppressive sugar, while being very distinct antigens. Initially, we analyzed the features of the CPS-specific serum Ab response to whole bacteria. S. suis-infected mice developed a very low (S. suis type 2) to undetectable (S. suis type 14) response restricted to the IgM isotype, and were unable to mount an efficient memory response after a secondary infection. A similar profile of response was obtained in S. suis type 2-infected pigs. We detected significant CPS-specific IgM titers in GBS-infected mice (type III or V). Nonetheless, the magnitude of the response remained globally low and no isotype switching was observed. Then, we examined the influence of the biochemistry of the CPS on these response profiles by conducting experiments with highly purified CPSs from these pathogens. Whereas the purified GBS type III CPS administrated to mice retained similar immunogenic properties as those observed during the infection with the intact bacteria, purified S. suis type 2 and GBS type V CPSs were no longer able to induce a specific Ab response. The analysis of the in vitro interaction between the CPSs and murine dendritic cells (DCs), crucial actors in the detection of pathogens and the orchestration of subsequent immune responses, revealed that these molecules stimulate the production of significant levels of chemokines through different receptors. Nevertheless, CPSs were unable to induce cytokine secretion and interfered with the ability of DCs to express BAFF, a key cytokine for B lymphocyte differentiation into plasma cells. The use of chemically desialylated CPSs demonstrated that sialic acid does not play a major immunosuppressive role in the development of the Ab response specific to purified S. suis or GBS CPSs, neither on the in vitro interaction between CPSs and DCs, nor on the profile of the in vivo response. Other biochemical properties intrinsic to these CPSs would be responsible for the inaptitude of the infected host to mount an adequate Ab response, and their identification will be a precious tool for a better understanding of the immunopathogenesis of S. suis and GBS, as well as for the development of efficient strategies to fight against these bacteria.

Follicular dendritic cells (FDCs) reside in primary B-cell follicles and in the light zones of germinal centers (GCs) in secondary follicles, where their dendrites interdigitate forming extensive networks intimately interacting with B-cells. In GCs, FDCs can be found at the edges attached to the supporting reticular fibers. They trap and arrange immune complexes (ICs) in vivo and in vitro in a periodic manner with 200–500Å spacing and provide both antigen-specific and non-specific accessory signals to B-cells. FDCs exist in resting and activated states, with two characteristically different phenotypes. In their activated state, FDCs upregulate the expression of accessory molecules and cytokines important in the FDC-B cell interaction in GCs. We sought to determine the mechanisms influencing the transition of FDCs from a resting to an activated state in GCs and their impact on T-cell dependent (TD) and independent (TI)-GC reactions (GCRs). We found that IC-FDC interactions via FDC-FcgammaRIIB induce the upregulation of FDC-FcgammaRIIB, -ICAM-1, and -VCAM-1, at both the protein and mRNA levels. We also reported for the first time the expression of TLR-4 on FDCs. Moreover, engagement of FDC-TLR4 with LPS activated NF-kappaB, up-regulated expression of important FDC-accessory molecules, including FcgammaRIIB, ICAM-1, and VCAM-1, and enhanced FDC accessory activity in promoting recall IgG responses. Moreover, IC-activated FDCs produced IL-6 and FDC-IL-6 promoted GCRs, somatic hypermutation (SHM) and IgG production. Further, we reported that binding of FDCs to collagen coated surfaces induced restoration of their dendritic processes and networks in vitro. In addition, we designed an FDC-supported in vitro model capable of induction and assessment of primary human antibody responses to protein antigens characterized by class-switching and affinity maturation. Uniquely, we generated TI immune responses to TD protein Ags in the complete absence of T cell help in vivo and in vitro. In the presence of FDC-associated second signals such as BAFF and C4BP, FDC- FcgammaRIIB-periodically trapped-ICs induced the production of Ag-specific IgM, GC-development and plasmablast-differentiation in anti-Thy-1-pretreated nude mice. Purified murine and human B cells cultured in vitro with IC-bearing FDCs also showed the production of antigen–specific IgM within just 48 h.

The virus SARS-CoV-2 gave rise to a global pandemic and several vaccines, whose efficiency needed to be evaluated, have been developed. Our immune system is regulated by several mechanisms that activate and inhibit immune response. PD-1 and its ligand PD-L1 are immune inhibitors with a possible correlation between the potency of the immune response and the number of inhibitors. The hypothesis of this study is that individuals with a lower antibody response after vaccination have higher levels of PD-1/PD-L1. Using an ELISA, the concentration of the proteins was measured from blood plasma from 19 individuals from the CoVacc Cohort, with known antibody response after one as well as two doses of vaccine. The study found a significant correlation between the inhibitors PD-1 and PD-L1 after both the first and the second dose. No correlation was found between the response of antibodies and PD-1/PD-L1 and the hypothesis is therefore rejected. It is possible that the interval between each dose of vaccine and the collection of blood plasma was not optimized for this study. It is also possible that the number of individuals that were included in this study was too low. Considering this result, more research should be conducted on the subject before an absolute conclusion can be drawn. / Viruset SARS-Cov-2 gav upphov till en global pandemi och flera vacciner vars effektbehövde utvärderas har utvecklats. Vårt immunförsvar regleras av flera mekanismersom samverkar genom att aktivera respektive hämma immunförsvaret. PD-1 och dessligand PD-L1 är immuninhibitorer med en möjlig korrelation mellan styrkan hosimmunsvaret och mängden inhibitorer. Hypotesen för denna studie är att individermed ett lägre antikroppssvar efter vaccination har högre nivåer av PD-1 och PD-L1.Med hjälp av en ELISA mättes koncentrationen av PD-1 och PD-L1 med blodplasmafrån 19 individer ur CoVacc kohorten med kända antikroppsnivåer som fått enrespektive två doser av vaccin mot COVID-19. Studien fann en signifikant korrelationmellan hämmarna PD-1 och PD-L1 både efter första och andra dosen. Ingenkorrelation hittades mellan antikroppsresponsen och nivåerna av PD-1 och PD-L1 ochhypotesen förkastas därför. Det är möjligt att tidpunkten för provtagning eftervaccindoserna inte valdes optimalt för denna undersökning. Det är också möjligt attför få individer ingick i studien. Mot bakgrund av detta bör mer forskning göras i ämnetinnan en absolut slutsats kan dras.